Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

KAND567 heading to capsules
November 2017
SHARING OPTIONS:

STOCKHOLM—Recipharm and Kancera have announced a collaboration to develop and manufacture KAND567, Kancera's drug candidate. KAND567 blocks the Fractalkine system, and testing in preclinical disease models has shown it can counteract the onset of autoimmune disorders, in addition to neuritis and pain connected with chemotherapy. Kancera hopes to treat patients in future trials with oral capsule formulations of the compound, and part of this new partnership entails Recipharm developing the necessary preparation for releasing KAND567 from capsules and manufacturing the pharmaceutical product.
 
“The decision to commence development of capsules for an active dosage of KAND567 shows that Kancera has reached an important milestone in the Fractalkine project. We are delighted to now be collaborating with Recipharm to produce the pharmaceutical product that will be used to study how KAND567 can help patients,” Thomas Olin, CEO of Kancera, said in a press release.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.